CHARLOTTESVILLE, Va., Oct. 23, 2013 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals announced today that its Chairman, Bankole A. Johnson, D.Sc., M.D., will deliver a keynote presentation on Personalized Medicine as part of the American Society of Addiction Medicine's (ASAM) 2013 State of the Art Course on Addiction Medicine. Prof. Johnson is scheduled to speak at 8:15 AM on Saturday, October 26, at the Crystal Gateway Marriot in Arlington, Virginia.
The State of the Art Course, which is being offered for the 8 th time in 2013, is recognized as the preeminent scientific program for addiction medicine professionals in the United States. Unlike typical conferences that feature multiple simultaneous workshops, the State of the Art Course is a 3-day curriculum that showcases series of lectures and audience interactions in a single plenary session. In 2013, it will be held at the Crystal Gateway Marriot in Arlington, Virginia, October 24-26, 2013.
Additional information about ASAM and the State of the Art Course can be found at the following link: http://www.asam.org/
About Dr. Bankole Johnson
Professor Bankole Johnson is a world-leading neuroscientist and a pioneer in the development of medications for the treatment of alcohol abuse. He has recently been appointed Chair of the Department of Psychiatry at the University of Maryland School of Medicine and also leads the new Brain Science Research Consortium Unit at the University of Maryland. The recipient of many awards, including the Jack Mendelson Award from the National Institutes of Health (NIH) in 2013, Prof. Johnson trained at Glasgow, London, and Oxford Universities. Additionally, he is the Principal Investigator on several NIH-funded research studies. A practicing physician, psychiatrist, and researcher for more than 25 years, Dr. Johnson has transformed our understanding of how abnormalities in the brain can promote addiction. These investigations also led him to discover drugs effective at alleviating alcohol addiction.
About ADial Pharmaceuticals, LLC
ADial Pharmaceuticals is a privately held pharmaceutical company developing medications for treating addiction diseases and disorders, including alcohol and drug addictions (cocaine, opioids, methamphetamines), as well as other addiction-like behaviors such as those related to obesity and eating disorders. The company's most advanced compound, AD04, specifically targets alcohol use disorder (previously called alcohol abuse and dependence) in patients with selected genotypes. For more information about ADial Pharmaceuticals, please visit http://www.adialpharma.com .
William Stilley, CEO (434) 422-9800 ext. 103
